ArticleBJU international2025
Positive surgical margin and oncological outcomes after robot-assisted radical prostatectomy in different Cancer of the Prostate Risk Assessment risk groups.
Article in BJU international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Bridging the Resolution Gap in Recurrent Prostate Cancer Imaging: Quantum Dots as PSMA-Targeted Optical Probes.ACS omega · 2026Review
- Engineering NIR Probes to Enhance Affinity and Clinical Workflow Compatibility for Prostate Cancer Imaging.Angewandte Chemie (International ed. in English) · 2026Article
- Robot-assisted radical prostatectomy for high-risk and locally advanced prostate cancer: a bibliometric and evidence-mapping analysis of oncologic safety, functional outcomes, lymph-node management, and multimodal treatment.Journal of robotic surgery · 2026Article
- 3D intraabdominal molecular imaging of primary prostate cancer, a hybrid approach that utilizes the robotic vision and dexterity.European journal of nuclear medicine and molecular imaging · 2026Article
- Pathological Tumour Volume Percentage as a Quantitative Biomarker of Biological Aggressiveness in High-Risk Prostate Cancer.Cancers · 2026Article
- PSMA PET/CT-guided pelvic lymph node dissection in patients with unfavorable intermediate- or high-risk prostate cancer.The Canadian journal of urology · 2026Article
- Robot-assisted radical prostatectomy reduces biochemical recurrence risk and improves urinary continence recovery compared with laparoscopic approach in high-risk localized prostate cancer after neoadjuvant therapy: a real-world propensity score-matched analysis.American journal of cancer research · 2026Article
- Engineering NIR probes to enhance affinity and clinical workflow compatibility for prostate cancer imaging.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveTo evaluate the impact of a positive surgical margin (PSM) in relation to the risk of biochemical recurrence (BCR) and additional treatment in different preoperative Cancer of the Prostate Risk Assessment (CAPRA) risk groups after robot-assisted radical prostatectomy (RARP). PATIENTS AND
methodsRetrospective cohort study of 1039 patients subjected to RARP for prostate cancer at a single European institution. PSM was stratified by extent (focal extensive). The CAPRA score was used for risk group stratification. BCR was defined as a prostate-specific antigen level >0.2 ng/mL. Additional treatment was defined as salvage radiotherapy (sRT) and/or androgen-deprivation therapy (ADT).
resultsIn total 227 patients had a PSM (21.8%). When compared to a negative surgical margin, an extensive PSM was associated with an increased risk of BCR (hazard ratio [HR] 2.16, 95% confidence interval [CI] 2.09-8.29; HR 3.76, 95% CI 2.33-6.06; HR 2.35, 95% CI 1.03-5.38) and sRT (HR 3.75, 95% CI 1.45-9.7; HR 4.57, 95% CI 2.47-8.43; HR 9.32, 95% CI 1.06-14.82) in the low-, intermediate- and high-risk groups, respectively. In high-risk patients a focal PSM was associated with an increased risk of BCR (HR 5.79, 95% CI 1.62-20.65), sRT (HR 9.32, 95% CI 1.7-50.95) and ADT (HR 4.11, 95% CI 1.08-15.57) whereas in low- and intermediate-risk patients a modest effect on BCR but no significant effect on sRT or ADT was found. We found no significant interaction between CAPRA risk group and PSM (P = 0.25).
conclusionsWhile an extensive PSM was associated with an increased risk of recurrence in all risk groups, a focal PSM was associated with additional treatment only among men with high-risk tumours.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.